NIOX®: the gold standard in FeNO1
Aerocrine is continuously developing and documenting measurement of fractional exhaled nitric oxide (FeNO) as a valuable tool in the management of airway inflammation.
Continuous ground-breaking development
- Aerocrine developed the first instrument for the measurement of FeNO
- Aerocrine has close collaboration with the world's leading FeNO scientists and clinicians
- Aerocrine will continue to lead the advancement of FeNO as a marker of airway inflammation and a leading valuable indicator of airway health
Aerocrine at a glance
Aerocrine is a medical technology company focused on improving the management and care of patients with inflammatory airway diseases, such as asthma. As the pioneer and leader in FeNO technology, Aerocrine markets NIOX MINO® and NIOX VERO® to monitor and manage airway inflammation. These products enable fast and reliable detection of airway inflammation to help identify, treat, and manage patients who might benefit from anti-inflammatory medicine.
Note: NIOX VERO® is currently only available in Europe (September 2014)
Reference: 1. Khalili B, Boggs PB, Bahna SL. Reliability of a new hand-held device for the measurement of exhaled nitric oxide. Allergy. 2007;62:1171-1174.